ROIV

Roivant Sciences
D

ROIV

Arincen25/100B

Roivant Sciences income statement 2019–2026

41.08M USD over the last twelve months, and 8.26M USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Mar 2026
FY2024
31 Mar 2025
FY2023
31 Mar 2024
FY2022
31 Mar 2023
FY2021
31 Mar 2022
FY2020
31 Mar 2021
FY2019
31 Mar 2020
Revenue
41.08M8.26M29.05M32.71M31.53M55.29M23.80M67.69M
Revenue growth
+102.09%-71.57%-11.19%+3.75%-42.97%+132.34%-64.85%—
Cost of revenue
4.65M1.29M911.00K1.60M3.03M8.97M2.06M1.13M
Gross profit
36.43M6.98M28.14M31.11M28.50M46.32M21.74M66.56M
Gross margin
88.68%84.44%96.86%95.11%90.38%83.78%91.36%98.33%
Research and development
712.09M681.81M550.41M439.91M454.06M483.04M236.63M263.22M
Selling, general and administrative
652.93M610.47M591.41M416.13M383.45M775.03M259.88M335.77M
Operating expenses
1.36B1.29B1.14B856.04M837.51M1.26B1.09B598.98M
-1.33B-1.29B-1.11B-824.93M-809.01M-1.21B-1.07B-532.43M
Operating margin
-3,233.02%-15,560.57%-3,833.27%-2,521.71%-2,565.85%-2,191.78%-4,500.52%-786.58%
Interest income
162.98M178.11M258.38M146.43M32.18M369.00K1.42M17.99M
Interest expense
———34.78M27.97M7.04M2.81M7.68M
Other non-operating income
1.03B1.02B432.09M5.39B-75.98M288.00M172.35M-28.56M
Pretax income
-297.18M-264.58M-681.59M4.57B-884.99M-923.75M-898.55M-560.99M
Income tax
104.35M133.33M48.17M21.50M4.08M369.00K1.69M7.12M
Effective tax rate
———0.47%————
-344.35M-299.77M-171.98M4.35B-1.01B-845.26M-809.23M1.20B
Net income growth
——-103.95%———-167.41%—
Net margin
-838.19%-3,629.19%-591.96%13,294.18%-3,200.22%-1,528.89%-3,400.86%1,773.57%
Basic shares
710.63M693.86M725.40M783.25M712.79M669.75M684.79M684.79M
Diluted shares
738.17M693.86M725.40M831.05M712.79M669.75M684.79M684.79M
Change in diluted shares
+5.78%-4.35%-12.71%+16.59%+6.43%-2.20%0.00%—
EPS (basic)
-0.48-0.43-0.245.55-1.42-1.26-1.181.75
EPS (diluted)
-0.54-0.43-0.245.23-1.42-1.26-1.181.75
EPS growth
——-104.59%———-167.43%—
EBITDA
-294.65M-261.23M-667.52M4.62B-838.17M-910.77M-895.74M-553.30M
EBITDA margin
-717.22%-3,162.59%-2,297.59%14,137.10%-2,658.31%-1,647.39%-3,764.40%-817.42%
EBIT
-297.18M-264.58M-681.59M4.60B-857.02M-916.71M-895.74M-553.30M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Roivant Sciences's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.